Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。
Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.